Key facts
- Arzeda’s last known valuation is $149.5M (Dec 2025).
- It has raised $109.2M across 6 recorded rounds; the latest was Seed Round ($4.5M) in Aug 2025.
- Notable investors include US National Science Foundation, U.S. Department of Energy, Sofinnova Partners, Arpa-E, Casdin Capital — 25 tracked in total.
- Arzeda has filed 7 Form Ds with the SEC since 2017, most recently Sep 2025 ($4.5M sold to 6 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 25 names
- ·Watchlist + deal alerts for Arzeda
Funding rounds
6 roundsAbout Arzeda
Developer of a synthetic biology technology designed to create new designer proteins and enzymes with less risk. The company specializes in computational protein design and develops a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals, and other advanced applications, enabling clients to develop custom proteins and enzymes that address business and sustainability needs across various industries.
- Sector
- Healthcare
- HQ
- Seattle, WA, United States
- Founded
- 2008
- Employees
- 66
- Website
- arzeda.com/
- Ownership
- Privately Held (backing)
Arzeda doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arzeda shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arzeda in its N-PORT filings yet. We sweep new filings monthly.